Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Mounjaro (tirzepatide) and Ozempic (semaglutide) have transformed weight loss treatment, with clinical trials showing 15-22% body weight reduction over 68 weeks. Both medications target appetite and blood sugar, but they activate different receptor pathways in your brain and gut. Choosing between them depends on your individual response profile, health history, and treatment goals.

How Tirzepatide and Semaglutide Work Differently

Semaglutide (Ozempic) activates one primary receptor pathway: the GLP-1 receptor in your brain and pancreas. This mechanism reduces hunger signals and slows stomach emptying, leading to sustained weight loss. The medication has been studied extensively in the STEP trial series, demonstrating consistent results across diverse patient populations.

Tirzepatide (Mounjaro) takes a dual-pathway approach by activating both GLP-1 and GIP receptors simultaneously. This combination targets appetite suppression and metabolic regulation through two independent signaling channels. Clinical data from the SURMOUNT trials showed tirzepatide produced approximately 22% body weight loss compared to 14% with semaglutide in direct comparison studies.

Clinical Trial Results: Which Showed Better Weight Loss?

The SURMOUNT-2 trial demonstrated that tirzepatide at its highest dose produced weight reductions of 22.5% over 68 weeks, while semaglutide achieved approximately 14.9% reduction at its maximum approved dose. However, tirzepatide users reported slightly higher rates of gastrointestinal side effects like nausea and vomiting during the titration phase. Both medications showed improvements in blood sugar control and cardiovascular markers, though tirzepatide's dual-pathway mechanism may offer additional metabolic benefits.

Individual response varies significantly based on your genetic makeup and metabolic factors. Some patients respond exceptionally well to semaglutide alone, while others require the dual GLP-1/GIP activation that tirzepatide provides. PlexusDx's Precision Peptide Genetic Test examines key variants like GLP1R rs6923761 and GIPR rs1800437 to predict which medication class aligns best with your biological response profile.

Side Effects: Tolerability and Adjustment Periods

Both medications commonly cause nausea, particularly during the first 2-4 weeks and when doses increase. Semaglutide users often tolerate the ramp-up period well, with side effects diminishing after the first month in most patients. Tirzepatide's side effect profile is similar but typically more pronounced during dose escalation, though many patients report adaptation within 4-6 weeks of continuing treatment.

Constipation and reduced appetite are expected effects that typically resolve with dietary adjustments and hydration. Serious adverse events are rare with both medications when used under proper medical supervision. PlexusDx clinicians monitor your tolerance throughout treatment and adjust your protocol if side effects become uncomfortable, ensuring you stay on a medication that fits your lifestyle.

Choosing Your Medication: What PlexusDx Recommends

Your ideal choice between tirzepatide and semaglutide depends on your weight loss goals, genetic predispositions, previous medication responses, and gastrointestinal tolerance. If you need rapid, aggressive weight loss and tolerate medication side effects well, tirzepatide's dual-pathway mechanism may offer superior results. If you prefer a gentler approach with proven long-term safety data, semaglutide remains highly effective, especially for patients with cardiovascular concerns.

PlexusDx compounded Tirzepatide Injection starts at $249/month across all commitment tiers with no flat per-compound pricing increases—your dose may go up, but your price won't. PlexusDx also offers Compounded Semaglutide Injection starting at $149/month, allowing you to access either medication affordably without insurance requirements. Adding the Precision Peptide Genetic Test ($99 after your first month) analyzes your GLP1R, GIPR, FTO, and MC4R variants to identify which pathway aligns with your metabolism, reducing trial-and-error and accelerating results.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide actually better than semaglutide for weight loss?

Clinical trials show tirzepatide produces slightly greater average weight loss (22% vs. 14%), but individual results vary significantly based on genetics and metabolism. Some patients respond equally well or better to semaglutide. PlexusDx's approach personalizes selection using genetic insights rather than assuming one medication works for everyone.

How do I know if my body will respond better to Mounjaro or Ozempic?

The Precision Peptide Genetic Test analyzes your GLP1R and GIPR variants to predict medication sensitivity and pathway activation patterns. This $99 test maps 14 pathways and 49 peptides, revealing whether dual-pathway stimulation (tirzepatide) or single-pathway focus (semaglutide) aligns with your genetic profile.

Can I switch from Ozempic to Mounjaro if one isn't working?

Yes, many patients successfully transition between medications under medical supervision. PlexusDx clinicians can switch you from semaglutide to tirzepatide or vice versa based on your response after 4-8 weeks of treatment. Your new medication maintains flat pricing—tirzepatide injection stays at $249/month regardless of dose.

Will I have more side effects with tirzepatide than semaglutide?

Tirzepatide users report slightly higher nausea rates during dose escalation, but side effects typically diminish within 4-6 weeks. Semaglutide often produces milder initial side effects. Both medications' tolerability improves significantly after the first month, and PlexusDx adjusts protocols if you experience persistent discomfort.

How much does compounded tirzepatide or semaglutide cost at PlexusDx?

PlexusDx Compounded Tirzepatide Injection starts at $249/month flat across all commitment tiers, while Compounded Semaglutide Injection starts at $149/month. No insurance is required, and both are HSA/FSA eligible. Your dose may increase over time, but your monthly price remains unchanged.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves